Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin plus dexmedetomidine for perioperative liver ischemia-reperfusion injury in laparoscopic liver resection
ChiCTR2200056487Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Feb 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of ulinastatin and dexmedetomidine in hepatic ischemia-reperfusion injury (HIRI) and hepatocellular carcinoma (HCC) (3 arms), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: α-glutathione S-transferase. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
ulinastatindexmedetomidine
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200056487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056487.